By accepting you will be accessing a service provided by a third-party external to

Psych Residents on COVID-19 Front Line; LSD in Phase II ADHD Trial

Illustration of a brain shaped maze.

Illustration of a brain shaped maze.

Even psychiatry residents are being recruited to care for COVID-19 patients in the hospitals. (STAT)

According to geotagged Twitter data, Michigan was the top state for COVID-19-related depression and anxiety tweets, followed by Missouri and Louisiana. (MLive)

The European ADHD Guidelines Group released additional guidance on initiating ADHD treatment in patients during the pandemic who haven't had an in-person baseline cardiovascular assessment. (The Lancet Child & Adolescent Health)

Mind Medicine announced it's entering into a phase IIa clinical trial testing LSD micro-dosing in adults with ADHD.

People with schizophrenia who switched to lurasidone (Latuda) after 12 months of treatment on risperidone (Risperdal) saw an improvement in symptoms along with reductions in weight, metabolic parameters, and prolactin levels. (BMC Psychiatry)

The San Francisco health department stated that it has been providing alcohol, tobacco, methadone, medical cannabis, and other substances to people suffering from addictions who are quarantined in city-leased hotels. (San Francisco Chronicle)

A meta-analysis determined that use of antidepressants during pregnancy didn't appear to put a child into any increased risk for autism. (American Journal of Psychiatry)

Arbor Pharmaceuticals announced the FDA accepted a new drug application for the company's investigational stimulant attention-deficit/hyperactivity disorder (ADHD) treatment AR19 -- an immediate-release amphetamine capsule for patients ages 3 and older.

Last Updated May 14, 2020

Hypertension-Related Deaths on the Rise in U.S., E...
Dementia and Heartburn Meds; AD Meets AI; Where Ar...


No comments made yet. Be the first to submit a comment
Already Registered? Login Here
Wednesday, 27 May 2020

Captcha Image